Cancer Guidelines Database

Access quality cancer guidelines from a single Canadian source

We've listed 141 guidelines under your selection of "Type of cancer". The most recent guidelines are first.

Bladder Cancer, Version 3.2020

Year: 2020
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with bladder cancer. Non-muscle-invasive urothelial bladder cancer, muscle-invasive urothelial bladder cancer, metastatic (Stage IVB) urothelial bladder cancer, non-urothelial carcinomas of the bladder, upper tract urothelial carcinoma (UTUC), urothelial carcinomas of the prostate, and primary carcinomas of the urethra are all specifically discussed. The guideline provides algorithms for diagnosis, staging, treatment, and follow-up.

Muscle-Invasive Bladder Cancer

Year: 2020
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults with a diagnosis of non-metastatic, muscle-invasive bladder cancer, including patients with a single regional lymph node metastasis in the true pelvis. The guideline examines the staging, treatment, and follow-up of these patients. Neoadjuvant chemotherapy, radical cystectomy with bilateral pelvic lymph node dissection, bladder preservation / combined modality approaches, adjuvant chemotherapy, and adjuvant radiotherapy are all discussed as management options. The guideline also addresses special situations, including small cell carcinoma of the bladder, urachal adenocarcinomas, and non-urothelial histology.

Renal Cell Carcinoma

Year: 2020
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults with a diagnosis, or suspected diagnosis of renal cell carcinoma (RCC). The guideline examines the appropriate diagnostic tests for RCC, as well as management and follow-up strategies for those who are diagnosed. Surgical options, systemic therapy and radiotherapy are specifically discussed.

Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline

Year: 2020
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for men with advanced prostate cancer, including newly diagnosed clinical high-risk disease, suspected or confirmed metastatic disease, recurrent disease, or progressive disease while under treatment. Recommendations are provided for the optimal use of imaging in this patient population. Conventional imaging (e.g. computed tomography (CT), bone scans, and/or prostate magnetic resonance imaging (MRI)) and next-generation imaging (e.g. positron emission tomography (PET), PET/CT, PET/MRI, and whole-body MRI) are discussed.

Society of Interventional Radiology Position Statement on the Role of Percutaneous Ablation in Renal Cell Carcinoma

Year: 2020
AGREE II score: Unavailable
Developer organization: Society of Interventional Radiology
This is a clinical practice guideline for patients with renal cell carcinoma. The guideline examines the role of percutaneous ablation in management, and comparisons are made to nephrectomy. Outcomes of interest include renal function, perioperative complications, and overall survival.

Bladder Cancer, Version 6.2020

Year: 2020
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with bladder cancer. Non-muscle-invasive urothelial bladder cancer, muscle-invasive urothelial bladder cancer, metastatic (Stage IVB) urothelial bladder cancer, non-urothelial carcinomas of the bladder, upper tract urothelial carcinoma (UTUC), urothelial carcinomas of the prostate, and primary carcinomas of the urethra are all specifically discussed. The guideline provides algorithms for diagnosis, staging, treatment, and follow-up.

Locally Advanced/Metastatic Bladder Cancer

Year: 2020
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults who have been diagnosed with locally advanced/metastatic bladder cancer (i.e. T4bNxM0, TxN2-3M0, TxNxM1). The guideline provides recommendations for staging of these patients, as well as treatment and follow-up options based on disease stage. Treatment modalities discussed include surgery, systemic therapy, and radiotherapy. For patients with metastatic cancer, palliative approaches are also discussed.

Bladder Cancer, Version 5.2020

Year: 2020
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with bladder cancer. Non-muscle-invasive urothelial bladder cancer, muscle-invasive urothelial bladder cancer, metastatic (Stage IVB) urothelial bladder cancer, non-urothelial carcinomas of the bladder, upper tract urothelial carcinoma (UTUC), urothelial carcinomas of the prostate, and primary carcinomas of the urethra are all specifically discussed. The guideline provides algorithms for diagnosis, staging, treatment, and follow-up.

An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

Year: 2020
AGREE II score: Unavailable
Developer organization: Cancer Care Ontario
This clinical practice guideline is an endorsement of the American Society for Radiation Oncology, American Society of Clinical Oncology, and American Urological Association's 2018 guideline titled Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. The guideline examines the use of hypofractionated radiation therapy compared to conventional fractionation in men with localized prostate cancer. Outcomes of interest include prostate control, toxicity, and quality of life.

Local Prostate Cancer

Year: 2020
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult men with a suspicion or recent diagnosis of localized prostate cancer. The guideline provides recommendations for the staging, management, and follow-up of these patients. Different management options are provided for patients with low-risk, intermediate-risk, or high-risk disease, and include active surveillance, radiotherapy, and surgery.

Advanced/Metastatic Prostate Cancer

Year: 2020
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients with diagnosed or suspected advanced/metastatic prostate cancer. The guideline examines the appropriate staging, treatment and follow-up for this patient population. Management, monitoring, systemic therapy, and radiotherapy are also discussed.

Penile Cancer, Version 2.2020

Year: 2020
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of squamous cell carcinoma (SCC) of the penis. The guideline examines the diagnosis, treatment, and follow-up for patients with this form of cancer. Outcomes of interest include optimizing therapeutic efficacy and minimizing treatment-related morbidity.

Testicular Cancer, Version 3.2020

Year: 2020
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with testicular germ cell tumours (GCTs). The guideline examines the clinical presentation, workup, primary treatment, and pathologic diagnoses of these patients. Separate recommendations are provided for different stages of pure seminomas and nonseminomas, and the guideline also discusses second-line and subsequent therapies for metastatic GCTs.

Biodegradable Rectal Spacers for Prostate Cancer Radiotherapy

Year: 2019
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for patients undergoing radiation treatment for localized prostate cancer. The guideline examines the use of biodegradable spacers for prostate cancer treatment. A topic of interest is biodegradable spacer insertion as a technology that may be used to decrease toxicity and maintain quality of life (QOL) in appropriately selected patients.

2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) Guideline: Management of Castration-Resistant Prostate Cancer (CRPC)

Year: 2019
AGREE II score: Unavailable
Developer organization: Canadian Urological Association
This clinical practice guideline is for patients with castration-resistant prostate cancer (CRPC). The guideline examines the management options available for these patients. Specific topics addressed include androgen-deprivation therapy (ADT), the addition or change of first-generation androgen receptor antagonists, and non-metastatic CRPC (nmCRPC).

Prostate Cancer: Diagnosis and Management

Year: 2019
AGREE II score: Available
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for patients with suspected or confirmed prostate cancer. The guideline provides recommendations for diagnosis, including the use of magnetic resonance imaging (MRI) and biopsy, treatment (i.e. radical treatment), follow-up, and active surveillance using multiparametric MRI.

Bladder Cancer, Version 4.2019

Year: 2019
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with bladder cancer. Non-muscle-invasive urothelial bladder cancer, muscle-invasive urothelial bladder cancer, metastatic (Stage IVB) urothelial bladder cancer, non-urothelial carcinomas of the bladder, upper tract urothelial carcinoma (UTUC), urothelial carcinomas of the prostate, and primary carcinomas of the urethra are all specifically discussed. The guideline provides algorithms for diagnosis, staging, treatment, and follow-up.

ACR Appropriateness Criteria Post-Treatment Surveillance of Bladder Cancer

Year: 2019
AGREE II score: Available
Developer organization: American College of Radiology
This is a clinical practice guideline for patients with bladder cancer. The guideline examines the appropriateness of various post-treatment surveillance procedures, including computerized tomography (CT), magnetic resonance imaging (MRI), ultrasounds, fluoroscopies, and radiographies. Outcomes of interest include disease recurrence and progression.

ACR Appropriateness Criteria Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Cancer

Year: 2019
AGREE II score: Available
Developer organization: American College of Radiology
This is a clinical practice guideline for patients with localized renal cell cancer. The guideline examines follow-up and active surveillance strategies for patients with treated or untreated disease. The appropriateness of various radiologic imaging procedures is evaluated, including magnetic resonance imaging (MRI), computerized tomography (CT), and ultrasound.

Incontinence After Prostate Treatment: AUA/SUFU Guideline

Year: 2019
AGREE II score: Available
Developer organization: American Urological Association
This is a clinical practice guideline for patients who have undergone prostate treatment, specifically radical prostatectomy, radiation treatment, or treatment of benign prostatic hyperplasia. The guideline discusses the management of incontinence in these patients. Specific topics addressed include the risk factors for incontinence, assessment of patients prior to intervention, as well as a stepwise approach to management. Treatment options such as physical therapy, medications and surgery are discussed.

Primary Urethral Carcinoma

Year: 2019
AGREE II score: Unavailable
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with primary urethral carcinoma. The guideline discusses, diagnostic evaluation and staging, prognosis, treatment, and follow-up. Specific diagnostic techniques examined include pelvic magnetic resonance imaging (MRI), computed tomography (CT) of the thorax and abdomen, urethrocystoscopy, biopsy, and urinary cytology. Treatment options are compared to those for penile cancer, and include distal urethrectomy, radiotherapy, and chemotherapy.

Adjuvant and Salvage Radiotherapy After Prostatectomy: ASTRO/AUA Guideline

Year: 2019
AGREE II score: Available
Developer organization: American Society for Radiation Oncology
This is a clinical practice guideline for patients with localized prostate cancer who have undergone radical prostatectomy. The guideline focuses on the use of radiotherapy to reduce the risk of prostate cancer recurrence and clinical progression of cancer in these patients, and provides specifications concerning the timing of radiotherapy while emphasizing the importance of communicating the potential risks and benefits to patients.

Testicular Cancer, Version 2.2020

Year: 2019
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with testicular germ cell tumours (GCTs). The guideline examines the clinical presentation, workup, primary treatment, and pathologic diagnoses of these patients. Separate recommendations are provided for different stages of pure seminomas and nonseminomas, and the guideline also discusses second-line and subsequent therapies for metastatic GCTs.

Diagnosis and Treatment of Early Stage Testicular Cancer Guideline: AUA Guideline

Year: 2019
AGREE II score: Available
Developer organization: American Urological Association
This is a clinical practice guideline for men with suspected or confirmed seminoma (clinical stages I, IIA, and IIB) or nonseminomatous germ cell tumours (NSGCTs). The guideline provides recommendations for the diagnosis, staging, treatment selection, and post-treatment surveillance of theses patients. The guideline's primary objective is to limit the burden of therapy and treatment-related toxicity without compromising cancer control. Specific outcomes of interest include treatment-related toxicity, disease recurrence, and survival.

Non-Muscle-Invasive Bladder Cancer

Year: 2019
AGREE II score: Available
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with non-muscle-invasive bladder cancer. The guideline examines the diagnosis, staging and classification, prediction of disease recurrence and progression, management, and follow-up of these patients. Specific management topics discussed include adjuvant treatment, treatment for failure of intravesical therapy, and radical cystectomy. Counselling of smoking cessation is also discussed.

Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline

Year: 2019
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for men with localized prostate cancer. The use of molecular biomarkers for the management of these patients is examined. The guideline specifically discusses patient selection, active surveillance, the identification of clinically significant disease, choosing postprostatectomy adjuvant versus salvage radiotherapy, and emerging questions such as the relative value of tissue biomarkers compared to magnetic resonance imaging (MRI).

Prostate Cancer Early Detection, Version 2.2019

Year: 2019
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline developed for adult men who have elected to participate in an early prostate cancer detection program. The guideline provides a set of sequential recommendations detailing screening and evaluation strategies for maximizing the detection of prostate cancer that is effectively treatable and that, if left undetected, represents a risk to the patient. Several techniques designed to improve the identification of significant cancer, while avoiding the detection of indolent disease, are highlighted, including imaging, biomarker testing, and biopsy.

Canadian Urological Association-Canadian Urologic Oncology Group Guideline on Metastatic Castration-Naive and Castration-Sensitive Prostate Cancer

Year: 2019
AGREE II score: Unavailable
Developer organization: Canadian Urological Association
This is a clinical practice guideline for patients with metastatic prostate cancer. The guideline examines various therapies for the treatment of metastatic castration-naive and castration-sensitive prostate cancer, including androgen-deprivation therapy, as well as local and external therapies. The prevention of osteoporosis, as well as opportunities for multidisciplinary consultation, are also discussed.

Complex Surgery and Perioperative Systemic Therapy for Genitourinary Cancer of the Retroperitoneum

Year: 2019
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for patients with metastatic testicular cancer, T3b, T4 or node-positive metastatic renal cell cancer (mRCC), as well as T3, T4 or node-positive upper tract urothelial carcinoma (UTUC). The guideline examines complex retroperitoneal surgical techniques, including the extent of resection and timing of surgery with respect to chemotherapy. Outcomes of interest include adverse events, hospital readmissions, and mortality.

Prostate Cancer, Version 4.2019

Year: 2019
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with prostate cancer. The guideline examines various treatment options including active surveillance, radical prostatectomy, radiation therapy, other local therapies, androgen deprivation therapy, chemotherapy, and immunotherapy. It also discusses risk stratification, imaging, and estimates of life expectancy. Recommendations are provided for the initial diagnosis, clinical assessment, and staging evaluation, as well as for treatment, which are based on both the level of risk, and specific disease present.

Renal Cell Carcinoma

Year: 2019
AGREE II score: Available
Developer organization: European Association of Urology
This is a clinical practice guideline for adults with renal cell carcinoma (RCC). The guideline provides recommendations for the diagnosis and staging, treatment, and follow-up of these patients. Diagnostic methods compared include physical examination, laboratory testing, as well as imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI). The guideline also examines nephron-sparing surgery, radical nephrectomy, surveillance, ablative therapies, and adjuvant therapy, as potential treatment options.

Upper Urinary Tract Urothelial Cell Carcinoma

Year: 2019
AGREE II score: Available
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with upper urinary tract urothelial cell carcinoma. The guideline examines the diagnosis, staging and classification systems, prognosis, management, and follow-up of these patients. Management options discussed include kidney-sparing surgery, radical nephroureterectomy, perioperative chemotherapy as an adjunct to radical nephroureterectomy, adjuvant radiotherapy after radical nephroureterectomy, adjuvant bladder instillation, metastasectomy, and systemic treatments.

Transrectal Ultrasound Guided Biopsy of the Prostate

Year: 2019
AGREE II score: Available
Developer organization: European Association of Urology Nurses
This is a clinical practice guideline on the use of transrectal ultrasound (TRUS)-guided biopsy for the diagnosis of prostate cancer. Pre-biopsy procedures, post-biopsy complications, and techniques used during biopsy are all addressed. Outcomes of interest include patient safety, dignity, and comfort.

Canadian Urological Association Guideline: Muscle-Invasive Bladder Cancer

Year: 2019
AGREE II score: Unavailable
Developer organization: Canadian Urological Association
This is a clinical practice guideline for patients with muscle-invasive bladder cancer. The guideline examines the diagnosis, staging, treatment, follow-up, supportive care, and palliative care for these patients. Treatment methods discussed include chemotherapy, surgical management and radiotherapy. Cystectomy pathology, as well as unresectable and oligometastatic disease are also addressed.

Penile Cancer, Version 2.2019

Year: 2019
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of squamous cell carcinoma (SCC) of the penis. The guideline examines the diagnosis, treatment, and follow-up for patients with this form of cancer. Outcomes of interest include optimizing therapeutic efficacy and minimizing treatment-related morbidity.

Testicular Cancer

Year: 2019
AGREE II score: Available
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with testicular cancer. The guideline examines the staging and classification, diagnosis, prognosis, management, and follow-up of these patients. Treatment methods for stage 1 germ cell tumours and metastatic germ cell tumours, the impact of treatment on fertility, as well as restaging and further treatment, are specifically discussed.

Muscle-Invasive and Metastatic Bladder Cancer

Year: 2019
AGREE II score: Available
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with muscle-invasive and metastatic bladder cancer. The guideline examines recommendations for diagnostic evaluation and disease management, guidance for assessing comorbidities, and options for follow-up based on site of recurrence and level of evidence. Outcomes of interest are overall survival, mortality and quality of life.

Prostate Cancer

Year: 2019
AGREE II score: Available
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with prostate cancer. The guideline examines the diagnostic evaluation, classification and staging, treatment, and follow-up of these patients. Treatment for metastatic prostate cancer and castration-resistant prostate cancer are specifically discussed, as is the management of prostate-specific antigen-only recurrence after treatment with curative intent.

Bladder Cancer, Version 4.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with bladder cancer. Non-muscle-invasive urothelial bladder cancer, muscle-invasive urothelial bladder cancer, metastatic (Stage IVB) urothelial bladder cancer, non-urothelial carcinomas of the bladder, upper tract urothelial carcinoma (UTUC), urothelial carcinomas of the prostate, and primary carcinomas of the urethra are all specifically discussed. The guideline provides algorithms for diagnosis, staging, treatment, and follow-up.

Consensus Statement on Definition, Diagnosis, and Management of High-Risk Prostate Cancer Patients on Behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG

Year: 2018
AGREE II score: Unavailable
Developer organization: Spanish Uro-Oncology Societies
This is a clinical practice guideline for patients with high-risk prostate cancer (PCa), defined as PCa patients who have a high probability of relapse, progression, and death from PCa. The guideline discusses the diagnosis and classification of these patients as high risk, as well as various treatment approaches, including external radiotherapy plus androgen deprivation therapy, radical prostatectomy with extended lymphadenectomy, external radiotherapy plus brachytherapy, hormone therapy, observation, and chemotherapy. Primary outcomes of interest include reductions in morbidity, cancer progression, recurrence, and mortality.

Castration-Resistant Prostate Cancer: AUA Guideline

Year: 2018
AGREE II score: Available
Developer organization: American Urological Association
This is a clinical practice guideline for patients with castration-resistant prostate cancer (CRPC). The guideline examines treatment options for six index patients that represent the most common clinical scenarios. Recommendations are based on the presence or absence of metastatic disease, the degree of symptoms, the patient's performance status, and whether or not their has been prior treatment with docetaxel-based chemotherapy. A scale for defining patient performance status is also provided.

Advanced / Metastatic Prostate Cancer

Year: 2018
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients who have been diagnosed with or are suspected of having advanced/metastatic prostate cancer. The guideline provides guidance on the staging, treatment, and follow up procedures for these patients. Topics of interest include radiotherapy techniques, the use of bone scans to assist in staging, and follow-up using active surveillance within a cancer clinic.

Penile Cancer, Version 2.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of squamous cell carcinoma (SCC) of the penis. The guideline examines the diagnosis, treatment, and follow-up for patients with this form of cancer. Outcomes of interest include optimizing therapeutic efficacy and minimizing treatment-related morbidity.

ACR Appropriateness Criteria Post-Treatment Follow-Up Prostate Cancer

Year: 2018
AGREE II score: Available
Developer organization: American College of Radiology
This is a clinical practice guideline for patients who have received treatment for prostate cancer. The guideline examines the various imaging modalities that can be effectively used for the follow-up of these patients. Variations of imaging modalities such as transrectal ultrasound (TRUS), magnetic resonance imaging (MRI), and computed tomography (CT) are discussed, and the appropriateness of different techniques is examined for different clinical situations.

Prostate Cancer Early Detection, Version 2.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline developed for adult men who have elected to participate in an early prostate cancer detection program. The guideline provides a set of sequential recommendations detailing screening and evaluation strategies for maximizing the detection of prostate cancer that is effectively treatable and that, if left undetected, represents a risk to the patient. Several techniques designed to improve the identification of significant cancer, while avoiding the detection of indolent disease, are highlighted, including imaging, biomarker testing, and biopsy.

Recommendations for Filgrastim Use in Adults by Disease Site

Year: 2018
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for adult oncology patients with neutropenia. The guideline examines the appropriate prescribing of filgrastim for these patients. Indications for which filgrastim should be used are discussed by disease site group. Disease site groups considered include breast, central nervous system, gastrointestinal, gynecologic, genitourinary, hematologic, and thoracic, amongst others.

Penile Cancer, Version 1.2019

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of squamous cell carcinoma (SCC) of the penis. The guideline examines the diagnosis, treatment, and follow-up for patients with this form of cancer. Outcomes of interest include optimizing therapeutic efficacy and minimizing treatment-related morbidity.

Kidney Cancer, Version 2.2019

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline specifically examines the initial evaluation, staging, diagnosis, clinical management options, and follow-up of patients with clear cell carcinoma and non-clear cell carcinoma. Pharmacologic agents discussed include pazopanib, sunitinib, and nivolumab.

Prostate Cancer, Version 2.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with prostate cancer. The guideline examines various treatment options including active surveillance, radical prostatectomy, radiation therapy, other local therapies, androgen deprivation therapy, chemotherapy, and immunotherapy. It also discusses risk stratification, imaging, and estimates of life expectancy. Recommendations are provided for the initial diagnosis, clinical assessment, and staging evaluation, as well as for treatment, which are based on both the level of risk, and specific disease present.

Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations: 2018

Year: 2018
AGREE II score: Available
Developer organization: Enhanced Recovery After Surgery Group
This is a clinical practice guideline on the perioperative care of patients undergoing colorectal surgery. including those with colorectal cancer. The guideline provides preadmission, preoperative, intraoperative and postoperative recommendations. The primary outcomes of interest are reductions in perioperative morbidity and mortality, as well as improvements in recovery and decreased duration of hospital stays after surgery.

Bladder Cancer, Version 1.2019

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with bladder cancer. Non-muscle-invasive urothelial bladder cancer, muscle-invasive urothelial bladder cancer, metastatic (Stage IVB) urothelial bladder cancer, non-urothelial carcinomas of the bladder, upper tract urothelial carcinoma (UTUC), urothelial carcinomas of the prostate, and primary carcinomas of the urethra are all specifically discussed. The guideline provides algorithms for diagnosis, staging, treatment, and follow-up.

Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

Year: 2018
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for men with localized prostate cancer. The guideline provides recommendations on the use of moderate hypofractionated and ultrahypofractionated external beam radiation therapy (EBRT), with particular reference to oncologic outcomes, toxicity, and quality of life.

Early Detection of Prostate Cancer: AUA Guideline

Year: 2018
AGREE II score: Available
Developer organization: American Urological Association
This is a clinical practice guideline for adult men who are at average risk of developing prostate cancer. The guideline examines screening methods for the early detection of prostate cancer for the purpose of reducing mortality. Outcomes of interest include prostate cancer incidence, mortality, quality of life, and the diagnostic performance of each of the tests, including the harms of testing (premature death and complications from both testing and biopsy).

Canadian Urological Association Guideline for Follow-up of Patients After Treatment of Non-Metastatic Renal Cell Carcinoma

Year: 2018
AGREE II score: Unavailable
Developer organization: Canadian Urological Association
This is a clinical practice guideline for patients who have been treated for non-metastatic renal cell carcinoma (RCC). The guideline examines the follow-up of these patients, and recommendations are provided for surveillance, clinical assessment, blood biochemistry tests, and imaging techniques.

Local Prostate Cancer

Year: 2018
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult men with a suspicion or recent diagnosis of localized prostate cancer. The guideline examines staging, treatment options, and follow-up for these patients. Management is discussed for low, intermediate, and high-risk disease. Treatment options considered include variations of radical prostatectomy, brachytherapy, external beam radiotherapy, cryosurgery, and active surveillance.

ACR Appropriateness Criteria Pretreatment Staging of Muscle-Invasive Bladder Cancer

Year: 2018
AGREE II score: Available
Developer organization: American College of Radiology
This is a clinical practice guideline for adults with muscle-invasive bladder cancer (MIBC). The guideline compares variations of imaging modalities for staging MIBC, such as x-ray, magnetic resonance imaging (MRI), fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), and computed tomography (CT). Outcomes of interest include diagnostic accuracy, sensitivity, specificity, and adverse health effects.

Testicular Cancer, Version 2.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with testicular germ cell tumours (GCTs). The guideline examines the clinical presentation, workup, primary treatment, and pathologic diagnoses of these patients. Separate recommendations are provided for different stages of pure seminomas and nonseminomas, and the guideline also discusses second-line and subsequent therapies for metastatic GCTs.

Prostate Cancer, Version 4.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with prostate cancer. The guideline examines various treatment options including active surveillance, radical prostatectomy, radiation therapy, other local therapies, androgen deprivation therapy, chemotherapy, and immunotherapy. It also discusses risk stratification, imaging, and estimates of life expectancy. Recommendations are provided for the initial diagnosis, clinical assessment, and staging evaluation, as well as for treatment, which are based on both the level of risk, and specific disease present.

Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Year: 2018
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for men with metastatic non-castrate prostate cancer being considered for treatment with androgen-deprivation therapy (ADT). The guideline examines the addition of docetaxel or abiraterone to ADT, and the resulting effects on overall survival (OS), progression-free survival (PFS), failure-free survival (FFS), prostate-specific antigen (PSA) response, overall response rate, and quality of life (QOL).

European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in Collaboration With the European Network for the Study of Adrenal Tumours

Year: 2018
AGREE II score: Available
Developer organization: European Society of Endocrinology
This is a clinical practice guideline for patients with adrenocortical carcinoma (ACC). The guideline examines the diagnostic criteria and management options for ACC. Topics of interest include a discussion of the best prognostic markers for ACC, treatment options including mitotane treatment, and supportive therapies.

Testicular Cancer, Version 1.2019

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with testicular germ cell tumours (GCTs). The guideline examines the clinical presentation, workup, primary treatment, and pathologic diagnoses of these patients. Separate recommendations are provided for different stages of pure seminomas and nonseminomas, and the guideline also discusses second-line and subsequent therapies for metastatic GCTs.

Kidney Cancer, Version 4.2018

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline specifically examines the initial evaluation, staging, diagnosis, clinical management options, and follow-up of patients with clear cell carcinoma and non-clear cell carcinoma. Pharmacologic agents discussed include pazopanib, sunitinib, and nivolumab.

Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement

Year: 2018
AGREE II score: Available
Developer organization: United States Preventive Services Task Force
This is a clinical practice guideline for asymptomatic men. The guideline discusses the appropriateness of periodic prostate-specific antigen (PSA) based screening for prostate cancer. Recommendations for screening are separated based on patient age.

ACR Appropriateness Criteria Hematospermia

Year: 2017
AGREE II score: Available
Developer organization: American College of Radiology
This is a clinical practice guideline for men and adolescents with hematospermia or hemospermia. The guideline discusses imaging techniques such as transrectal ultrasound (TRUS) and magnetic resonance imaging (MRI), and their use in the identification of hematospermia's etiology. The guideline examines the appropriateness of different imaging techniques based on patient age, severity of bleeding, and presence of other relevant symptoms.

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline

Year: 2017
AGREE II score: Available
Developer organization: American Urological Association
This is a clinical practice guideline for the management of localized prostate cancer. The guideline provides a clinical framework stratified by cancer severity to guide the care plan and reviews management options including active surveillance, observation/watchful waiting, prostatectomy, radiotherapy, cryosurgery, high intensity focused ultrasound (HIFU), and focal therapy. Shared decision making is highlighted, and guidance is provided on outcome expectations and management.

Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline

Year: 2017
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for the management of patients with clinically localized small renal masses (SRM). The guideline examines management options for small renal masses, which includes biopsies, active surveillance for patients with significant comorbidities and limited life expectancy, partial nephrectomy (PN), percutaneous thermal ablation, radical nephrectomy, and referral to a nephrologist. Outcomes of interest include recurrence-free survival, disease-specific survival, and overall survival.

Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion

Year: 2017
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This is a provisional clinical opinion (PCO) for chemotherapy-naive men with castration-resistant prostate cancer (CRPC). This PCO examines second-line hormonal therapy and provides recommendations on staging, treatment, follow-up, and palliative care for men with CRPC. Outcomes of interest include overall survival, adverse events, quality of life, and treatment efficacy (defined as response in prostate-specific antigen values).

Consensus Statements on the Management of Metastatic Prostate Cancer From the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology

Year: 2017
AGREE II score: Unavailable
Developer organization: Hong Kong Urological Association
This is a clinical practice guideline for patients with metastatic prostate cancer (mPCa). The guideline examines the management of patients with castration-naïve mPCa and those with metastatic castration-resistant prostate cancer (mCRPC). The use of predictive markers in mCRPC, sequencing treatment in mCRPC, managing men with oligometastases, as well as the staging and monitoring of mCRPC treatment, are also discussed.

EAU Guidelines on Testicular Cancer

Year: 2017
AGREE II score: Unavailable
Developer organization: European Association of Urology
This is a clinical practice guideline for the diagnosis and treatment of patients with testicular cancer. The guideline examines the pathology of the illness, staging and classification systems, diagnostic evaluation, prognosis, disease management, and follow-up. Topics of interest include diagnostic tools, treatment with chemotherapy, and discussion of quality of life and long-term toxicities after curative treatment.

EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer

Year: 2017
AGREE II score: Available
Developer organization: European Association of Urology
This is a clinical practice guideline for the management of muscle-invasive and metastatic bladder cancer. The guideline provides recommendations on prevention, staging, imaging, diagnosis, treatment, and follow-up. Treatment options such as neoadjuvant chemotherapy, radiotherapy, and radical surgery are discussed. Other topics of interest include risk factors, comorbidities, quality of life, and pelvic organ preservation techniques.

Guidelines for Treatment of Renal Injury During Cancer Chemotherapy 2016

Year: 2017
AGREE II score: Unavailable
Developer organization: Japanese Society of Nephrology
This is a clinical practice guideline for patients with renal cancer, and is especially relevant to those with comorbid chronic kidney disease. The guideline examines the treatment of chemotherapy-induced renal injury in these patients. Specific topics discussed include the assessment of renal function during chemotherapy, the appropriateness of biomarker-based assessments for the diagnosis of chemotherapy-induced renal injury, and whether or not chemotherapy doses should be reduced in patients with decreased renal function.

Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Bladder Carcinoma

Year: 2017
AGREE II score: Available
Developer organization: Society for Immunotherapy of Cancer
This is a clinical practice guideline on the appropriate use of immunotherapy for the treatment of patients with bladder cancer, specifically non-muscle invasive bladder cancer, muscle invasive bladder cancer, and advanced bladder cancer. The guideline addresses issues related to the definition of risk categories, patient selection, toxicity management, clinical endpoints, as well as the combination and sequencing of therapies. The guideline also highlights areas for future direction and development to advance the use of immunotherapy in bladder cancer treatment.

Renal, GI, and Peripheral Nerves: Evidence-Based Recommendations for the Management of Symptoms and Care for Patients With Multiple Myeloma

Year: 2017
AGREE II score: Unavailable
Developer organization: International Myeloma Foundation
This is a clinical practice guideline for patients with multiple myeloma (MM). The guideline provides recommendations for the prevention and management of organ health-related toxicities, and gives best practice recommendations for optimal nursing care of this patient population. Specific outcomes examined include myeloma-induced renal impairment, gastrointestinal symptoms, and peripheral neuropathy.

EAU Guidelines on Urothelial Carcinoma of the Upper Urinary Tract

Year: 2017
AGREE II score: Available
Developer organization: European Association of Urology
This is a clinical practice guideline for the management of urothelial carcinoma of the upper urinary tract (UTUC). The guideline provides recommendations on diagnosis, staging, treatment, and follow-up. Prognostic factors, predictors of survival and recurrence, as well as risk stratification are also discussed. Outcomes of interest include diagnostic accuracy, overall survival, recurrence rates, and adverse effects.

Guidance for Kyphoplasty and Vertebroplasty for Cancer Patients in Ontario: Recommendations Report 2017

Year: 2017
AGREE II score: Unavailable
Developer organization: Cancer Care Ontario
This guideline provides recommendations on use of vertebroplasty or kyphoplasty as treatment options for cancer patients with vertebral compression fractures. The guideline outlines clinical criteria for when vertebroplasty, kyphoplasty, or focal tumour ablation (FTA) assisted vertebroplasty/kyphoplasty should be performed, and provides recommendations on selecting the most appropriate procedure. The role of radiation treatment, absolute contraindications, and service provider requirements are also discussed.

Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management

Year: 2017
AGREE II score: Unavailable
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult males with potentially curable prostate cancer. The guideline examines surgical procedures and outcomes for radical prostatectomy (RP), while specifically addressing the extent of resection, acceptable positive margins, nerve-sparing techniques, pelvic lymph node dissection (PLND), and the recommended procedures for handling and processing RP specimens. Incontinence, erectile dysfunction, rectal injury, and blood transfusion are discussed as surgical complications that need to be limited.

Update of the ICUD‑SIU Consultation on Upper Tract Urothelial Carcinoma 2016: Treatment of Localized High‑Risk Disease

Year: 2017
AGREE II score: Unavailable
Developer organization: International Consultation on Urological Diseases
This is a clinical practice guideline for patients with localized high-risk upper tract urothelial carcinoma (UTUC). The guideline examines the treatment of these patients using surgery, neoadjuvant and adjuvant chemotherapy, and adjuvant radiotherapy. Surgical techniques discussed include radical nephroureterectomy, regional lymph node dissection, renal-sparing surgery, and salvage surgery after renal-sparing approaches. The management of the distal ureter during nephroureterectomy and prevention of bladder cancer recurrence following nephroureterectomy are also discussed.

Performance of Needle Biopsy of the Prostate for Men With Suspected or Established Prostate Cancer: Recommendation Report

Year: 2017
AGREE II score: Unavailable
Developer organization: Cancer Care Ontario
This recommendation report addresses "best practices" for prostate needle biopsies. Guidance is provided on the spectrum of prostate needle biopsy practices, including patient preparation, biopsy techniques, specimen submission to the laboratory, processing of the biopsy specimen, information to include on the requisition and pathology report, and operational issues. Facility requirements are also reviewed.

Renal Mass and Localized Renal Cancer: AUA Guideline

Year: 2017
AGREE II score: Available
Developer organization: American Urological Association
This is a clinical practice guideline for patients with localized renal masses that are suspicious for renal cell carcinoma. The guideline discusses the evaluation, diagnosis, staging, and management of these renal masses. The management options discussed include partial nephrectomy, radical nephrectomy, thermal ablation, and active surveillance.

Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update

Year: 2017
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for patients with newly diagnosed prostate cancer who require or choose active treatment, and are not receiving active surveillance by choice or lack of suitability. The guideline examines the efficacy of brachytherapy, as compared to and combined with external beam radiation therapy (EBRT) and radical prostatectomy (RP). The guideline also considers which isotopes should be used for low-dose rate (LDR) brachytherapy to maximize clinical outcomes.

EAU Guidelines on Renal Cell Carcinoma

Year: 2017
AGREE II score: Available
Developer organization: European Association of Urology
This is a clinical practice guideline for adult patients with renal cell carcinoma (RCC). The guideline examines the staging, diagnosis, prognosis, treatment, and follow-up of these patients. Management recommendations are provided for treating localized RCC, locally advanced RCC, advanced/metastatic RCC, and recurrent RCC. The epidemiology, etiology, and pathology of RCC are also discussed.

EAU Guidelines on Non-Muscle-Invasive Bladder Cancer (TaT1 and CIS)

Year: 2017
AGREE II score: Available
Developer organization: European Association of Urology
This is a clinical practice guideline for the management of non-muscle-invasive bladder cancer. Recommendations are provided for diagnosis, staging, treatment, and follow-up. The guideline also discusses how to predict the short-term and long-term risks of disease recurrence and progression, as well as the stratification of patients into risk groups. Treatment options are presented based on these risk groups. Management of side effects is also discussed.

ACR Appropriateness Criteria Prostate Cancer-Pretreatment Detection, Surveillance, and Staging

Year: 2017
AGREE II score: Available
Developer organization: American College of Radiology
This is a clinical practice guideline for adult men with prostate cancer or clinically suspected prostate cancer. The guideline examines the various imaging modalities that can be effectively used to manage these patients, during initial diagnosis, staging, and active surveillance. Variations of imaging modalities such as transrectal ultrasound (TRUS), magnetic resonance imaging (MRI), and computed tomography (CT) are discussed, and the appropriateness of different techniques is examined for different clinical situations.

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

Year: 2017
AGREE II score: Available
Developer organization: American Urological Association
This is a clinical practice guideline for the management of non-metastatic muscle-invasive urothelial bladder cancer in adults. The guideline examines the initial evaluation, treatment, follow-up, and survivorship of affected patients, and discusses approaches to counseling and the role of patient preferences throughout. Specific treatment options considered include neoadjuvant and adjuvant chemotherapy, radical cystectomy, pelvic lymphadenectomy, and bladder preserving approaches such as maximal transurethral resection of bladder tumours, partial cystectomy, primary radiation therapy, and multi-modal bladder preserving therapy.

Renal Cell Carcinoma

Year: 2017
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline examines the clinical management of RCC, including diagnosis, treatment, and follow up. The primary outcomes of interest are survival, recurrence, and quality of life.

EAU – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer

Year: 2017
AGREE II score: Available
Developer organization: European Association of Urology
This is a clinical practice guideline for adult patients with prostate cancer. The guideline examines the screening, diagnosis, staging, treatment, and follow-up of these patients. Treatment options considered include deferred treatment, radical prostatectomy, definitive radiotherapy, and hormonal therapy. Management of metastatic prostate cancer, prostate cancer in older men, prostate-specific antigen-only recurrence after treatment, and castration-resistant prostate cancer are also discussed, as well as the epidemiology and etiology of prostate cancer, and quality of life outcomes.

EAU Guidelines on Primary Urethral Carcinoma

Year: 2017
AGREE II score: Available
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with primary urethral carcinoma (UC). The guideline provides recommendations on the diagnosis and treatment of UC. Staging and classification systems for UC are also discussed. Outcomes of interest include detection rate, overall survival, complications, and toxicity.

The Use of Targeted Therapies in Patients With Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Updated Guideline 2017

Year: 2017
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adults with inoperable locally advanced or metastatic renal cell cancer. The guideline provides recommendations on optimal targeted therapies and compares different drug treatments and combinations of treatments. Outcomes of interest include overall quality of life, overall survival, toxicity, fatigue, and other adverse events.

Referral of Suspected Prostate Cancer by Family Physicians and Other Primary Care Providers

Year: 2016
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline on the diagnosis of prostate cancer. The guideline examines effective diagnostic methods and provides recommendations on testing and referrals. Outcomes of interest include diagnostic accuracy, sensitivity, and specificity. Other topics of discussion include factors associated with delayed referral and risk factors that are predictive of prostate cancer.

Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Renal Cell Carcinoma

Year: 2016
AGREE II score: Available
Developer organization: Society for Immunotherapy of Cancer
This is a clinical practice guideline on the use of immunotherapy for the treatment of patients with metastatic renal cell carcinoma (mRCC). Specifically, the guideline addresses the role of high-dose interleukin-2 (HD IL-2) therapy, the selection of patients for IL-2-based regimens and the criteria for those choices, the current role of interferon and its use in conjunction with bevacizumab, the identification of biomarkers of response to immunotherapy, the sequencing of immunotherapy with the anti-vascular endothelial growth factors agents, the management of patients with central nervous system metastases, and the potential role and sequencing of new immunotherapy agents including the programmed death 1 / programmed death ligand 1 (PD-1/PD-L1) pathway inhibitors.

Recommendations for Filgrastim Use in Adults by Disease Site

Year: 2016
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline to guide appropriate prescribing of filgrastim in adults. The guidelines looks at a variety of disease sites and is intended as a guide to facilitate a shared approach to the appropriate use of filgrastim. In order provide clarity surrounding the indications in which filgrastim should be used, the recommendations are presented by disease site.

Myeloid Growth Factors – Version 2.2016

Year: 2016
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the use of myeloid growth factors in adult patients with solid tumours and non-myeloid malignancies. Benefits and risks are reviewed, the role of biosimilars is discussed, and recommendations are provided for prophylactic and therapeutic uses of both granulocyte and granulocyte-macrophage colony stimulating factors (CSFs). Recommendations are also given regarding the use of CSFs in the hematopoietic cell transplant setting. Outcomes of interest include efficacy of CSFs, mortality, length of hospitalization, toxicity, and adverse effects.

Prostate Cancer – Version 3.2016

Year: 2016
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews diagnostic assessment and management of prostate cancer. The guideline discusses risk stratification, molecular testing, and imaging for clinical assessment and staging workup. Management options reviewed include observation, active surveillance, radical prostatectomy, radiation therapy, androgen deprivation therapy, chemotherapy, and immunotherapy, with treatment recommendations stratified by risk. Outcomes of interest include survival and adverse effects of treatment.

Magnetic Resonance Imaging for Pre-Treatment Local Staging of Prostate Cancer

Year: 2016
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for magnetic resonance imaging (MRI) for pre-treatment local staging of prostate cancer. The use of MRI for pre-treatment local staging is juxtaposed with the ways in which prostate cancer is conventionally detected which includes prostate-specific antigen (PSA) screening, digital rectal examination (DRE), and biopsy-confirmed diagnosis by transrectal ultrasonography (TRUS). The guideline therefore explores the performance and diagnostic accuracy of MRI, as well as the impact of pre-treatment local staging by MRI on patient on patient outcomes, biochemical recurrence, changes in treatment planning (including nerve- sparing surgery), changes in stage classification, and surgical margin status in men with newly diagnosed biopsy-confirmed prostate cancer who are under consideration for radical treatment.

Clinical practice guidelines PSA Testing and Early Management of Test-Detected Prostate Cancer

Year: 2016
AGREE II score: Available
Developer organization: Prostate Cancer Foundation of Australia
A clinical practice guideline for middle-aged and older men at risk for prostate cancer who are considering, or have decided to have, a PSA test. The guideline examines supporting informed decision making for PSA testing, recommended protocols, and diagnosis and management for abnormal results. Outcomes of interest include reducing over-diagnosis and improved cumulative mortality.

Human Papillomavirus Vaccination Guideline Update: American Cancer Society Guideline Endorsement

Year: 2016
AGREE II score: Available
Developer organization: American Cancer Society
This is a clinical practice guideline for females and males between the ages of 9 and 26. The guideline examines the use of the human papillomavirus (HPV) vaccination for the purposes of cancer prevention. The ages at which routine vaccination and catch-up vaccination should occur are discussed, as well as which vaccines should be used for males and females. Special populations such as men who have sex with other men and immunocompromised persons are also addressed.

Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline

Year: 2016
AGREE II score: Available
Developer organization: American Urological Association
This is a clinical practice guideline for patients with non-muscle invasive bladder cancer. Recommendations are provided on diagnostic procedure, risk stratification, variant histologies, urine markers, and treatment options including TURBT/Repeat resection, intravesical therapy, BCG/maintenance, and chemotherapy BCG combinations. BCG relapse and salvage regimens are reviewed as is the role of cystectomy and cystoscopy. Additionally, recommendations are provided for risk adjusted surveillance and follow-up strategies.

Permanent Source Brachytherapy for Prostate Cancer

Year: 2016
AGREE II score: Available
Developer organization: American College of Radiology
A clinical practice guideline for patients with prostate cancer. The guideline examines permanent source brachytherapy in low and high risk patients combined with external-beam radiation therapy and/or androgen deprivation therapy. Outcomes of interest include quality of life, quality of life, complication rates, and biochemical outcomes.

ACR Appropriateness Criteria Locally Advanced, High-Risk Prostate Cancer

Year: 2016
AGREE II score: Available
Developer organization: American College of Radiology
A clinical practice guideline for adults with locally advanced, high-risk prostate cancer. The guideline examines aggressive approaches to prostate cancer treatment, focusing on intensive local therapy through external beam radiation. Outcomes of interest include improved local control resulting in improved outcomes via combination therapy.

Testicular Germ Cell Tumours

Year: 2016
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients with testicular germ cell tumours (GCTs). The guideline examines appropriate management and follow-up strategies for different stages of the two main histological types of testicular GCTs: seminomas and nonseminomas. Outcomes of interest include recurrence and overall survival.

Palliative Radiotherapy: Bleeding and Gastrointestinal Obstruction

Year: 2016
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for palliative oncology patients 18 years of age or older with low grade/ low volume/ malignancy-associated urogenital or gastrointestinal bleeding, or with malignant gastrointestinal obstruction, compression or invasion. External beam radiotherapy (EBRT) with or without , brachytherapy, stent placement, and surgical bypass are discussed as therapeutic options. Outcomes of interest include clinical improvement of symptoms, quality of life, and survival.

Kidney Cancer – Version 1.2017

Year: 2016
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline provides recommendations for the initial evaluation and staging, treatment, and follow-up for adults with various stages of kidney cancer. Topic areas discussed in the guideline include: imaging, surgery, lymph node dissection, targeted therapy, and supportive care.

Bladder Cancer – Version 2.2016

Year: 2016
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline discusses evaluation, treatment (primary and secondary) options, and follow-up care for patients with bladder cancer. Specific workup and treatment recommendations are provided for non-muscle invasive disease, muscle invasive disease, upper genitourinary tract (GU) tumours, urothelial carcinomas of the prostate, and primary carcinoma of the urethra. Non-urothelial carcinomas of the bladder are also discussed.

ACR Appropriateness Criteria External Beam Radiation Therapy Treatment Planning for Clinically Localized Prostate Cancer

Year: 2016
AGREE II score: Available
Developer organization: American College of Radiology
A clinical practice guideline for patients with localized prostate cancer undergoing external beam radiation. The guideline examines treatment planning and delivery, with specific intervention details for multiple clinical variants. Outcomes of interest include improved clinical outcomes and reduced GI toxicity.

The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Prostate Carcinoma

Year: 2016
AGREE II score: Available
Developer organization: Society for Immunotherapy of Cancer
This is a clinical practice guideline for patients with prostate cancer. The guideline provides recommendations on the use of immunotherapy for the treatment of these patients, with recommendations separated based on the stage of disease (i.e. whether metastatic or non-metastatic, castration-sensitive or castration-resistant). Specific topics discussed include issues related to patient selection, monitoring of patients during and after treatment, and sequence/combination with other anti-cancer treatments.

The Diagnosis, Treatment, and Follow-Up of Renal Cell Carcinoma

Year: 2016
AGREE II score: Unavailable
Developer organization: German Society of Hematology and Oncology (DGHO)
This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline discusses diagnosis, treatment, and follow-up, and provides specific recommendations on topics such as the primary treatment of RCC without metastases, systemic treatment for metastatic RCC, neoadjuvant/adjuvant therapy, as well as the resection and radiotherapy of metastases.

Bone Health and Bone-Targeted Therapies for Prostate Cancer

Year: 2016
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for men with prostate cancer who are receiving androgen deprivation therapy (ADT). The guideline examines the effectiveness of therapies that target bone, which can mitigate the effects of ADT on bone health. Outcomes of interest include fracture, bone mineral density (BMD), osteoporosis, skeletal-related events (SREs), bone metastasis, pain, patient-reported quality of life (QOL), and overall survival.

Penile Cancer – Version 2.2016

Year: 2016
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with squamous cell carcinoma (SCC) of the penis. The guideline reviews risk factors and clinical presentation, and provides recommendations for clinical staging, management of primary legions, management of regional lymph nodes, surveillance, and management of metastatic disease. Surgery, radiotherapy, and chemotherapy are reviewed as treatment options.

Prostate Cancer Early Detection – Version 2.2016

Year: 2016
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for healthy male patients who have elected to participate in early screening of prostate cancer. The guideline reviews types of early detection testing, mainly PSA and DRE, provides recommendations on baseline evaluation, risk assessment, and early detection evaluation, provides guidance on indications for biopsy and direction for management of biopsy results. Special topics of interest include biomarker testing and biopsy technique.

2016 EAU Guidelines on Urothelial Carcinomas of the Upper Urinary Tract

Year: 2016
AGREE II score: Available
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with, or suspected of having, upper urinary tract urothelial carcinomas (UTUCs). The guideline reviews diagnostic assessment, staging, treatment, and follow-up. Treatment recommendations are provided based on whether the disease is localized or advanced and include radical nephroureterectomy, conservative surgery, adjuvant topical agents, chemotherapy, and radiotherapy. Outcomes of interest include risk factors, sensitivity and specificity of diagnostic tests, survival (recurrence-free, disease-free, and overall), disease progression, morbidity, and mortality.

ACR Appropriateness Criteria Staging of Testicular Malignancy

Year: 2016
AGREE II score: Available
Developer organization: American College of Radiology
This is a clinical practice guideline for the staging of testicular malignancy. Recommendations are made with consideration of the following variant: staging testis tumour, diagnosed by orchiectomy. The guideline also discusses tumour markers and provides an overview of imaging modalities.

EAU – ESTRO – SIOG Guidelines on Prostate Cancer

Year: 2016
AGREE II score: Available
Developer organization: European Association of Urology
This is a clinical practice guideline for male patients diagnosed with or suspected of having prostate cancer. The guideline reviews classification and staging, diagnostic evaluation, disease management, and follow-up care. Side effects of local treatment and health-related quality of life in prostate cancer survivors are also discussed. Outcomes of interest include overall survival, cancer-specific survival, development of metastatic disease, sensitivity and specificity of diagnostic procedures, and side effects of treatment.

Focal Tumour Ablation in Ontario: Recommendations Report 2015

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for patients with a variety of cancers, including lung, liver, and kidney tumours, with a specific focus on patients with hepatocellular carcinoma (HCC) or liver metastases. The guideline examines the effectiveness of thermal ablation, which encompasses radiofrequency ablation (RFA) and microwave ablation, as well as transcatheter arterial chemoembolization (TACE), alone or in combination with other strategies. The guideline outlines patient clinical criteria, criteria for service providers, and system-level criteria.

2015 EAU Guidelines on Renal Cell Carcinoma (Update March 2015)

Year: 2015
AGREE II score: Available
Developer organization: European Association of Urology
This is a clinical practice guideline for the management of renal cell carcinoma. The guideline examines the diagnosis, staging, treatment, and follow-up of renal cell carcinoma, with treatment recommendations stratified by disease stage. Therapeutic strategies are also discussed. Outcomes of interest include overall survival, cancer-specific survival, recurrence-free survival, and quality of life.

2015 EAU Guidelines on Urothelial Carcinomas of the Upper Urinary Tract (Limited Update March 2015)

Year: 2015
AGREE II score: Unavailable
Developer organization: European Association of Urology
This clinical practice guideline provides recommendations for urothelial carcinomas of the upper urinary tract. The guideline covers epidemiology, etiology, and pathology, staging, diagnosis, prognosis, disease management, and follow-up. Issues addressed in the guideline include: risk factors, symptoms, imaging, preoperative factors, predictive tools, and management for both localized and advanced disease.

Prostate Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement

Year: 2015
AGREE II score: Unavailable
Developer organization: American Society of Clinical Oncology
A clinical practice guideline for prostate cancer survivors. The guideline examines health promotion, screening for second primary cancers, and assessment of physical and psychosocial effects. Outcomes of interest include effective referral, minimized psychological harm, and reduced recurrence.

Renal Cancer in Adults: Diagnosis, Treatment and Follow-up

Year: 2015
AGREE II score: Available
Developer organization: Belgian Health Care Knowledge Centre
A clinical practice guideline for adult patients with renal cancer. The guideline examines treatment through surgery and ablative therapy, diagnosis, and follow-up. Outcomes of interest include improved prediction of cancer-specific survival through Karakiewicz nomograms and improved evidence for microwave ablation.

Prostate Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This clinical practice guideline provides recommendations on management of prostate cancer, including diagnosis and screening, management stratified by risk, and follow up care. Active surveillance, surgery (radical prostatectomy), external beam radiotherapy (EBRT), low dose rate (LDR) brachytherapy, cryosurgery, High Intensity Focused Ultrasound (HIFU), Androgen Deprivation Therapy (ADT), and systemic therapies are discussed as treatment options. Bone health is also reviewed. Outcomes of interest include survival and recurrence.

Bladder Cancer, Version 2.2015

Year: 2015
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline discusses evaluation, treatment (primary and secondary) options, and follow-up care for patients with bladder cancer. Specific workup and treatment recommendations are provided for non-muscle invasive disease, muscle invasive disease, upper genitourinary tract (GU) tumours, urothelial carcinomas of the prostate, primary carcinoma of the urethra. Non-urothelial carcinomas of the bladder are also discussed.

Bladder Cancer: Diagnosis and Management

Year: 2015
AGREE II score: Available
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for adults age 18 years and older who are suspected of having or are newly diagnosed with bladder cancer or cancer of the urethra, or diagnosed with recurring bladder cancer or cancer of the urethra. The guideline provides recommendations on diagnosis, staging, and management of muscle-invasive, non-muscle invasive, locally advanced, and metastatic bladder cancers. Management of treatment side effects and follow-up care is also discussed. Outcomes of interest include survival (overall, disease-free), disease-related morbidity and mortality, treatment-related morbidity and mortality, psychological well-being, quality of life, admissions to hospital after diagnosis, adverse events, and cost-effectiveness.

2015 EAU Guidelines on Primary Urethral Carcinoma (Limited Update 2015)

Year: 2015
AGREE II score: Unavailable
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with, or suspected of having, primary urethral carcinoma. The guideline reviews diagnostic assessment, staging, and treatment. Treatment options include penile-preserving and urethral-sparing surgery, urethrectomy, radiotherapy, cisplatinum-based chemotherapy, chemoradiotherapy, transurethral resection (TUR), Bacille-Calmette-Guérin (BCG), and cystoprostatectomy with extended pelvic lymphadenectomy. Outcomes of interest include survival, sensitivity of diagnostic tests, local cure rate, local recurrence rate, and local tumour control rate.

Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer

Year: 2015
AGREE II score: Available
Developer organization: Cancer Care Ontario
A clinical practice guideline for the diagnostic assessment of clinically significant prostate cancer. The guideline examines Multiparametric magnetic resonance imaging as an alternative to traditional transrectal ultrasound–guided systematic biopsy in order to reduce over- or under-diagnosis of clinical results. Outcomes of interest include detection rate of clinically significant prostate cancer, improved survival, and improved predictive value.

CUA Guidelines on the Management of Non-Muscle Invasive Bladder Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: Canadian Urological Association
A clinical practice guideline for patients with non-muscle invasive bladder cancer. The guideline examines management, emphasizing intravesical therapy and prognostic factors. Outcomes of interest include lower recurrence and longer disease-free intervals with transurethral resection of bladder tumours.

2015 EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer (Limited Updated March 2015)

Year: 2015
AGREE II score: Unavailable
Developer organization: European Association of Urology
This is a clinical practice guideline on muscle-invasive and metastatic bladder cancer. This is an update to the European Association of Urology's 2000 guidelines on bladder cancer and provides recommendations related to staging, diagnostic evaluation, management, and follow-up. Issues addressed include: imaging, surgery, chemotherapy, radiotherapy, and recurrence.

Evidenced-based Clinical Practice Guideline for Upper Tract Urothelial Carcinoma (Summary–Japanese Urological Association, 2014 Edition)

Year: 2015
AGREE II score: Unavailable
Developer organization: Japanese Urological Association
This is a clinical practice guideline for patients with upper tract urothelial carcinoma (UTUC). The guideline provides recommendations on diagnosis and treatment, with discussions on surgery, radiotherapy, chemotherapy and other anticancer drug therapies. Topics include surgical techniques, the use of neoadjuvant versus adjuvant chemotherapy, postoperative follow-up care, the use of ureteroscopic kidney-sparing surgery, instillation of BCG or other anticancer drugs into the upper urinary tract, treatment of metastatic or recurrent UTUC, and use of radiotherapy alone as treatment. Epidemiology is also discussed.

Castration-Resistant Prostate Cancer: AUA Guideline

Year: 2015
AGREE II score: Available
Developer organization: American Urological Association
This is a clinical practice guideline for patients with castration-resistant prostate cancer (CRPC). The guideline provides recommendations on different patient types, with consideration to whether patient is symptomatic/asymptomatic, if cancer is metastatic, poor vs good performance status, and whether or not patient has previously received docetaxel chemotherapy. Outcomes of interest include survival (overall survival, progression-free, metastasis-free) PSA PFS, PSA decline, measurable disease response, adverse events/side-effects of treatment, quality of life (QOL), skeletal-related events (SREs), pain-free survival, and pain response.

Intravesical Instillation with Mitomycin C or Bacillus Calmette-Guérin in Non-muscle Invasive Bladder Cancer

Year: 2015
AGREE II score: Available
Developer organization: European Association of Urology Nurses
A clinical practice guideline for the treatment of non-muscle invasive bladder cancer. The guideline examines care pathways for nursing in the administration of instravesical instillation, including chemotherapy and immunotherapy. Important aspects of this guideline include safety and exposure procedures and patient management during the administration of the instillation medication.

Penile Cancer, Version 3.2015

Year: 2015
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with squamous cell carcinoma (SCC) of the penis. The guideline reviews risk factors and clinical presentation, and provides recommendations for clinical staging, management of primary legions, management of regional lymph nodes, surveillance, and management of metastatic disease. Surgery, radiotherapy, and chemotherapy are reviewed as treatment options.

The 2015 CUA-CUOG Guidelines for the Management of Castration-Resistant Prostate Cancer (CRPC)

Year: 2015
AGREE II score: Unavailable
Developer organization: Canadian Urological Association
This is a clinical practice guideline for the management of castration-resistant prostate cancer (CRPC). The guideline considers the role of bone supportive agents and palliative radiation in the overall management of CRPC. Due to the fact CRPC includes a wide range of disease types, different management options are considered including for those with rising PSA non metastatic CRPC, metastatic CRPC without symptoms or minimally symptomatic, metastatic CRPC with symptoms, and for patients with CRPC and bone metastases.

Follow-up Care and Psychosocial Needs of Survivors of Prostate Cancer

Year: 2015
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for men with prostate cancer who have received treatment with curative intent. The frequency by which prostate-specific antigen (PSA) levels should be tested in these patients is discussed, and the guideline also examines appropriate diagnostic testing techniques for instances in which biochemical (BC) recurrence occurs. The guideline also discusses psychosocial issues, sexual health, fatigue, urinary health, and bowel heath outcomes associated with prostate cancer treatment.

Lower Urinary Tract Symptoms in Men: Assessment and Management

Year: 2015
AGREE II score: Available
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline offers best practice advice on the care of men with lower urinary tract symptoms (LUTS). The guideline provides recommendations on the effective evidence-based management of LUTS. Areas covered in the guideline include discussion of: initial assessment, conservative management, surgery, and drug treatment. The guideline also provides recommendations on how to best ensure men with LUTS have access to care that addresses their psychosocial issues.

ACR Appropriateness Criteria Renal Cell Carcinoma Staging

Year: 2015
AGREE II score: Available
Developer organization: American College of Radiology
A clinical practice guideline for renal cell carcinoma staging. The guideline examines staging through multiple imaging modalities, including CT, MRI, PET, bone scans, chest radiography, ultrasound, and arteriography. Outcomes of interest include diagnostic accuracy, reduced cost, and detection of metastasis.

Prostate Cancer Early Detection, Version 2.2015

Year: 2015
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for healthy male patients who have elected to participate in early screening of prostate cancer. The guideline reviews types of early detection testing, mainly PSA and DRE, provides recommendations on baseline evaluation, risk assessment, and early detection evaluation, provides guidance on indications for biopsy and direction for management of biopsy results. Special topics of interest include biomarker testing and biopsy technique.

Prostate Cancer, Version 1.2016

Year: 2015
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews diagnostic assessment and management of prostate cancer. The guideline discusses risk stratification, molecular testing, and imaging for clinical assessment and staging workup. Management options reviewed include observation, active surveillance, radical prostatectomy, radiation therapy, androgen deprivation therapy, chemotherapy, and immunotherapy, with treatment recommendations stratified by risk. Outcomes of interest include survival and adverse effects of treatment.

Kidney Cancer, Version 1.2016

Year: 2015
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for kidney cancer. The guideline provides recommendations for the initial evaluation and staging, treatment, and follow-up for adults with various stages of kidney cancer. Topic areas discussed in the guideline include: imaging, surgery, lymph node dissection, targeted therapy, and supportive care.

Oncogenetic Testing, Diagnosis and Follow-up in Birt-Hogg-Dubé Syndrome, Familial Atypical Multiple Mole Melanoma Syndrome and Neurofibromatosis 1 and 2

Year: 2015
AGREE II score: Available
Developer organization: Belgian Health Care Knowledge Centre
This is a clinical practice guideline for patients at risk of Birt-Hogge-Dubé Syndrome, the familial atypical multiple mole melanoma syndrome and neurofibromatosis 1&2, either based on clinical suspicion or family history. The guideline reviews indications for genetic testing, clinical utility of specific genetic tests, and follow-up depending on test results and family history. Impact of genetic counselling and test on patient behaviour and distress levels is also reviewed.

Testicular Cancer, Version 1.2016

Year: 2015
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with testicular cancer. The guideline provides recommendations on clinical presentation, diagnostic workup, risk assessment, and treatment. Management options are stratified by stage and cancer type (seminoma or nonseminoma). Second-line therapy for metastatic germ cell tumours is reviewed with recommendations provided for palliative therapy and treatment of brain metastases.

Suspected Cancer: Recognition and Referral

Year: 2015
AGREE II score: Available
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for patients of all age groups suspected of having cancers including lung and pleural, upper gastro-intestinal, lower gastrointestinal, breast, gynecological, urological, skin, head and neck, brain and central nervous system, haematological, sarcomas, and childhood cancers. Recommendations are provided on recognition and referral or investigations of cancer in primary care. Outcomes of interest include quality of life, sensitivity and specificity of diagnostic tests and signs/symptoms, positive and negative predictive values of diagnostic tests and signs/symptoms, and cost effectiveness.

Guideline for Referral of Patients with Suspected Prostate Cancer by Family Physicians and Other Primary Care Providers

Year: 2015
AGREE II score: Available
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for referral of patients with suspected prostate cancer by family physicians and other primary care providers. More specifically, the guidelines provide recommendations for referral based on digital rectal examination (DRE) findings and prostate-specific antigen (PSA) test results. The research questions that guided the development of recommendations included: what signs, symptoms, and other clinical features that present in primary care are predictive of prostate cancer; what is the diagnostic accuracy of investigations commonly considered for patients presenting with signs and/or symptoms of prostate cancer; and what major, known risk factors increase the likelihood of prostate cancer in patients presenting with signs and/or symptoms of prostate cancer.